Solaris Endovascular’s DEScover Trial Completes Enrollment

January 13, 2026—Solaris Endovascular, Inc. announced that the DEScover clinical trial has completed enrollment.

According to the company, the prospective, multicenter clinical study is evaluating the Solaris DE sirolimus-eluting covered stent for the treatment of vascular disease in dialysis access circuits. Specifically, it seeks to determine if the Solaris DE can reduce edge restenosis and the need for repeat interventions.

The company stated that the study includes both native arteriovenous fistula (AVF) and prosthetic arteriovenous fistula graft (AVG) patients. It is designed to evaluate safety and target lesion primary patency (TLPP) outcomes compared with standard percutaneous transluminal angioplasty in AVF patients and single-arm treatment in AVG patients.

Leonardo Harduin, MD, is Principal Investigator of the trial.

“Completing DEScover enrollment ahead of schedule was an important scientific and clinical milestone,” commented Dr. Harduin in the company’s press release. “Based on what we’ve seen so far, Solaris DE has the potential to be the long-awaited solution to vascular access patency.”

The Solaris Endovascular press release also noted that interim 6-month data from the DEScover trial were presented at the TCT 2025 scientific symposium in October. The data demonstrated 95% overall TLPP, including 100% patency in the AVG cohort and 91% patency in AVF patients treated with Solaris DE, with no device-related serious adverse events reported at 30 days, reported the company.